ABEO vs. AMLX, COYA, FGEN, ALLK, VTGN, ACET, PDSB, RGLS, DMAC, and NVCT
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Amylyx Pharmaceuticals (AMLX), Coya Therapeutics (COYA), FibroGen (FGEN), Allakos (ALLK), Vistagen Therapeutics (VTGN), Adicet Bio (ACET), PDS Biotechnology (PDSB), Regulus Therapeutics (RGLS), DiaMedica Therapeutics (DMAC), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical preparations" industry.
Abeona Therapeutics (NASDAQ:ABEO) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.
80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 5.3% of Abeona Therapeutics shares are held by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Abeona Therapeutics has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. Amylyx Pharmaceuticals' return on equity of 4.14% beat Abeona Therapeutics' return on equity.
Abeona Therapeutics presently has a consensus price target of $21.00, suggesting a potential upside of 417.24%. Amylyx Pharmaceuticals has a consensus price target of $28.67, suggesting a potential upside of 1,557.03%. Given Amylyx Pharmaceuticals' higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Abeona Therapeutics.
Abeona Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.68, meaning that its stock price is 168% less volatile than the S&P 500.
Abeona Therapeutics received 489 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 70.31% of users gave Abeona Therapeutics an outperform vote while only 62.50% of users gave Amylyx Pharmaceuticals an outperform vote.
Amylyx Pharmaceuticals has higher revenue and earnings than Abeona Therapeutics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Abeona Therapeutics had 4 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 6 mentions for Abeona Therapeutics and 2 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.89 beat Abeona Therapeutics' score of 1.06 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.
Summary
Amylyx Pharmaceuticals beats Abeona Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Abeona Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
